Abstract:Sumoylation is a versatile posttranslational modification that regulates a wide spectrum of cellular activities and is involved in a number of human diseases. Cardiomyopathy is the leading cause of heart failure. Whether and how sumoylation is implicated in cardiomyopathy has not been well investigated. To address this issue, we generated a number of independent transgenic mouse lines that express constitutively active SUMO-2 in hearts (SUMO-2-Tg). Four of five SUMO-2-Tg mouse lines exhibited cardiomyopathy with various severities, ranging from acute heart failure leading to early death to hypertrophic cardiomyopathy which developed gradually as mice aged. An increase in apoptosis was observed in the SUMO-2-Tg hearts prior to the occurrence of any other discernible heart phenotypes. Adenovirus-mediated expression of SUMO-2 in cultured cardiomyocytes significantly increased Annexin V staining, indicating that SUMO-2 directly promoted the apoptotic process. We further revealed that SUMO-2 was directly involved in regulation of apoptosis at least partially via targeting calpain 2 (Capn2) and its natural inhibitor calpastatin (CAST). SUMO attachment to CAST mainly promoted its turnover, thus inhibiting CAST activity. On the other hand, SUMO-2 linkage to Capn2 increased its capacity to promote apoptosis, as evidenced by the observation that adenovirus-aided expression of SUMO-fused Capn2 (SUMO-Capn2) in cultured cardiomyocytes significantly promoted Annexin V staining compared with free Capn2. We also observed that SUMO-2/3 conjugation was significantly increased in the human failing hearts compared with the control hearts. Correspondingly, elevated levels of SUMO-2/3-conjugated Capn2 and CAST were detected in the human failing hearts vs. control hearts. Thus, elevated SUMO-2 conjugation led to increased apoptosis and cardiomyopathy at least partially via targeting calpain-calpastatin proteolytic system. The present study uncovers a direct regulation of the apoptotic pathway by the SUMO-2/3 conjugation pathway.

SUMO Modification in Apoptosis

SUMOylation modification-mediated cell death

The Ubiquitin-Proteasome System in Apoptosis and Apoptotic Cell Clearance

Post-Translational Modification of SUMOylation and Cancer: A Brief Review

SUMOylation Homeostasis in Tumorigenesis

SUMO proteases: from cellular functions to disease

Research advance on the mechanism of abnormal small ubiquitin-like modifier in tumorigenesis and development

The post-translational modification, SUMOylation, and cancer (Review)

The Critical Roles of the SUMO-Specific Protease SENP3 in Human Diseases and Clinical Implications

Research progression on biologic function and effect of SUMO-specific proteinase

Mechanisms and functions of SUMOylation in health and disease: a review focusing on immune cells

Protein SUMOylation Modification and Its Associations with Disease

SUMO and the robustness of cancer

Protein SUMOylation and disease

[Sumo-Specific Protease 1 and Cancer].

DeSUMOylation: An Important Therapeutic Target and Protein Regulatory Event.

[Sumoylation and Its Role in Hematological Disease].

Paralogue-Specific Roles of SUMO1 and SUMO2/3 in Protein Quality Control and Associated Diseases

Research progression in post-translational protein modification sumoylation in cancer

Abstract 030: Cardiac-specific Expression of Constitutively Active Sumo-2 in Mice Leads to Cardiomyopathy

SUMO modification regulates the transcriptional activity of XBP1.